Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Kenworth showcases its T680 X15N demo truck with Hexagon Agility fuel system

First trucks with 15-liter natural gas engine begin production in Q316 May, 2024: Hexagon Agility, the world’s leading provider of (renewable) natural gas (CNG/RNG) fuel systems, announced today its fuel system will be showcased on the Kenworth T680 natural gas truck with the new X15N engine at ACT Expo 2024. Kenworth Truck Company, one of the top three truck OEMs in North America stated in a news release  it will begin production of Kenworth T680 and

Metso launches the first diesel-electric Lokotrack EC range units

Metso Corporation’s press release on May 16, 2024, at 10:00 a.m. EESTMetso’s Lokotrack[®] EC range brings a new diesel-electric power line to the aggregates market. All the process functions of the range are electric, significantly reducing the use of hydraulic oil needed in the crushing operations. All Lokotrack EC range units can be powered with external electricity. In its Lokolaunch event in Tampere, Finland, Metso launched the first two products of the new EC range. Lokotrack LT400J is a 68-ton mobile jaw crusher designed for the primary crushing of hard rock and recycled aggregates.

Peikko and ZECH receive fire classification for their DELTABEAM[®] and CREE slab system

Peikko Group Corporation and the construction company ZECH Bau Holding GmbH are continuing their successful collaboration in a new project. Peikko and ZECH conducted joint fire tests with the wood-concrete hybrid slab from CREE Deutschland GmbH, a subsidiary of ZECH Building SE, and the DELTABEAM[®] Composite Beam from Peikko. The tests were necessary because there were no official fire tests for these and comparable hybrid slabs. The fire behavior tests on Peikko's DELTABEAM[®] Composite Beam and the CREE wood-concrete hybrid system were carried out by PAVUS, a renowned fire

43 of Telia’s mobile sites in Estonia are now supported by solar panels

Alongside Telia’s mobile masts in Estonia, 43 solar installations have been constructed over the past year, enabling tens of thousands of Telia’s customers in the country to use mobile services powered by solar energy, when conditions are right. Renewable energy solutions developer Sunly City and Telia Estonia entered into a comprehensive agreement last spring, under which Sunly City will construct solar installations near approximately 100 of Telia’s mobile masts in the country by the end of 2024. To date, 43 solar installations have been constructed alongside Telia’s mobile

Notice of Annual General Meeting of Nordhealth AS

16 May 2024 – Notice is given to the shareholders of Nordhealth AS (the "Company") that the Annual General Meeting will be held on 30 May 2024 at 10:00 hours (CET).The meeting will be conducted as a virtual meeting only. Shareholders may also participate by means of advance votes or provide a proxy with voting instructions. Pre-registration is needed for attending the meeting, see Appendix 1 of the attached notice. Deadline for the pre-registration and registration of advance votes and proxies is 28 May 2024 at 16:00 hours (CET). For further information, please contact: Charles

Navamedic ASA: Renewed contract for delivering antibiotics to Norwegian hospitals

Oslo, 16 May 2024 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, has received confirmation of an extension of its contract with The Norwegian Hospital Procurement Trust (Sykehusinnkjøp HF) for continued delivery of antibiotics to Norwegian hospitals. The contract runs to 31 January 2027. The contract is awarded by The Norwegian Hospital Procurement Trust on behalf of the four health regions in Norway as part of the LIS tender programme (in Norwegian: legemiddelinnkjøpssamarbeid) for antibiotics. The

Volvo expands its range of biodiesel-powered trucks

A full range of new Volvo truck models can now be powered by 100% biodiesel, offering another renewable fuel choice for customers looking to reduce CO\2\ emissions from transport here and now.Volvo Trucks is expanding its model offers adapted for biodiesel B100. This is yet another move in line with the company’s strategy to reduce the climate impact of its trucks. Volvo Trucks has one of the industry’s broadest ranges of renewable fuel options, including biodiesel, HVO (Hydrotreated Vegetable Oils) and biogas. B100 is now available for a wide selection of engines in the Volvo FL, FE, FM,

Björn Ingemanson is proposed as the new chairman of Ziklo Bank

The nomination comittee of Ziklo Bank, formerly known as Volvofinans Bank, has proposed Björn Ingemanson as the new chairman of the bank. Björn is proposed to succeed Urmas Kruusval, who is stepping down after leading the bank, both as CEO 1990-1999, and then as chairman of the board since 2007. Björn Ingemanson has many years of solid experience in the financial and automotive industry. During the past 25 years he has been marketing manager and CEO at Ziklo Bank, marketing director for Volvo Cars Japan, European manager for Volvo Financial Services, CFO and division manager for Volvo

Quartiers enters into growth-oriented partnership with Catella Corporate Finance

Quartiers Properties AB (publ) ("Quartiers" or the "Company"), listed on Nasdaq First North, has entered into a partnership with Catella Corporate Finance (Catella) for the expansion of Boho Club in Europe. The first task of the partnership is to refinance the Company's loan structure and to raise funds for the expansion of Boho Club Marbella in accordance with the detailed plan that is currently being developed. In addition, Catella will assist in the identification and sourcing of financing for new hotel projects with the aim of establishing a strategy for the European expansion of the

AEGIRBIO study published in Multiple Sclerosis and Related Disorders journal

Lund May, 16 2024 – AegirBio AB, a forefront leader in saliva-based diagnostics solutions, announces today the the findings of our recent study published in the Multiple Sclerosis and Related Disorders journal. The research sheds light on the importance of understanding the interaction between a drug called natalizumab and a protein in the body called IgG4 for patients undergoing this treatment."Our study not only provides valuable insights into the effectiveness of natalizumab treatment for MS patients but also serves as proof of the effectiveness of our monitoring technology,” said Marco

Rejlers helps Borealis accelerate sustainable transition

Rejlers has signed a 3-year framework agreement with Borealis in Stenungsund. The agreement covers a wide range of engineering, procurement and project management services that will contribute to Borealis' transformation projects during the period.Borealis is a leading provider of innovative solutions in polyolefins and base chemicals. The company has ambitious sustainability goals and has collaborated with Rejlers for many years. The agreement covers various services, such as maintenance, studies, basic engineering, as well as EPCM (Engineering, Procurement, and Construction Management)

Invitation to the presentation of Calliditas´s interim report January – March 2024

Calliditas´s interim report for the first quarter, January – March 2024 will be published in Swedish and English on Thursday 23 May 2024 at 07.00 a.m. CET.A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén. The presentation will be given in English. Link to the webcast:  Calliditas Therapeutics Q1 Report 2024 (financialhearings.com) 

ExpreS2ion announces financial results for the first quarter of 2024

Hørsholm, Denmark, 16 May 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its first quarter financial results for 2024. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments: “We are starting 2024 invigorated by our new strategy with clear objectives, the strong progress of our proprietary pipeline, and a broadly validated platform. The overall conditions for early-stage biotech funding remain challenging and selective. Against this backdrop, we have established our

Notice of the Annual General Meeting in LEAX Group AB (publ)

The shareholders in LEAX Group AB (publ), reg. no 556658–4479, are hereby given notice to the Annual General Meeting on Thursday 13 June 2024 at 10:00 at the company’s premises at Nya Hamnvägen 4, SE-731 36 Köping.EXERCISE OF VOTING RIGHTS Those who wish to exercise their voting rights at the Annual General Meeting must: · be entered as a shareholder in the share register kept by Euroclear Sweden AB on Tuesday 4 June 2024 or, if the shares are registered in the name of a nominee, request that the nominee registers the shares in their own name for voting purposes in such time that

Notice of Annual Shareholders´ Meeting in InCoax Networks AB

The shareholders of InCoax Network AB (publ), Reg. No. 556794-1363, are hereby invited to attend the annual shareholders’ meeting on Thursday 13 June 2024 at 09.00 in the company’s premises at Ideon Science Park, Mobilvägen 10, Lund.The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.    Right to participate and notification  Shareholders wishing to participate in the annual shareholders’ meeting must:  · be listed in the company’s share register kept by Euroclear Sweden

Notice to the Annual General Meeting of Cline Scientific AB

The shareholders of Cline Scientific AB, 556867-8238, ("Cline Scientific" or "the Company"), are hereby invited to the annual general meeting on Tuesday June 18, 2024 in the Company's premises at AstraZeneca BioVentureHub. Since passage into AstraZeneca's (AZ) premises requires registration, this and registration of shareholders takes place in AZ's main entrance between 16:15-16:30, Pepparedsleden 1, 43153 Mölndal. Information about the decisions made by the AGM will be published on 18 June 2024 via the AGM Kommuniqué.Right to participate and registration Anyone who is registered as a

Forbes 30 under 30 listed fashion designer duo Paolina Russo released its first SPINNOVA outfit at Challenge the Fabric

Award-winning Paolina Russo released their first outfit made with SPINNOVA® fibre at Challenge the Fabric event in Milan. The outfit shows that it is possible to create colourful and playful designs while being sustainable. Forbes 30 under 30 listed designer duo Paolina Russo released their first outfit made from a fabric containing sustainable SPINNOVA® fibre (21%) and cotton (79%). The denim-like fabric is woven in Finland, and it is dyed for example using natural pigments sourced from pine and indigo. The outfit was designed with the purpose of showing that sustainable

Kongsberg Automotive wins a new contract worth over EUR 13 million in estimated lifetime revenue

Kongsberg, May 16, 2024: Kongsberg Automotive (KA) has secured a new contract worth over EUR 13 million in estimated lifetime revenue for battery coolant pipes. The contract, awarded by a global Original Equipment Manufacturer (OEM) is for coolant pipes connected to a new generation of battery packs used in trucks. The manifold distributes coolant within the battery clusters in the truck’s battery cells and has a unique IP67 connection (water and dust tightness standard) to the truck’s chassis cooling system. For this three-year contract, KA will start production in 2025 and will

Year-end report 1 April 2023 - 31 March 2024

Fourth quarter (1 January - 31 March 2024) · Net sales amounted to SEK 5,091 million (5,267). · Operating profit before amortisation of intangible non-current assets (EBITA) increased by 1 percent and amounted to SEK 763 million (758) corresponding to an EBITA margin of 15.0 percent (14.4). · Operating profit amounted to SEK 649 million (660) corresponding to an operating margin of 12.7 percent (12.5). · Profit after tax amounted to SEK 451 million (461) and earnings per share before/after dilution amounted to SEK 1.60 (1.65). Full year (1 April 2023 - 31 March 2024) ·

Founders named European Inventor Award finalists

Faron Pharmaceuticals Oy   (“Faron” or the “Company”)     Faron founders and bexmarilimab developers selected as finalists for the European Inventor Award 2024   Press Release, May 16, 2024 at 9:00 (EEST) / 7:00 AM (BST) / 2:00 AM (EDT)     -          Dr. Markku Jalkanen and Dr. Sirpa Jalkanen, Faron’s co-founders, have been nominated as one of three finalists in the ‘SMEs’ category of prestigious European Patent Office Awards -          Nominated in recognition of research developing bexmarilimab, an investigational immunotherapy optimising clinical outcomes

Citycon divests Kongssenteret in Norway

CITYCON OYJ   Investor News   16 May 2024 at 9.00 hrsCitycon has signed an agreement to sell Kongssenteret in Kongsvinger, Norway. The sales price is close to the latest IFRS fair value of the asset. The transaction is estimated to close by the end of May.“The divestment follows Citycon’s strategy to focus on larger, grocery and municipal service-anchored urban hubs with direct connection to public transportation. The transaction showcases the attractiveness and desirability of necessity-based, inflation protected Nordic retail assets to investors as the transaction market is picking up”,

SUPERNOVA Trial Met COVID-19 prevention endpoint

16 May 2024 SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population Positive high-level results from the SUPERNOVA Phase III COVID-19 pre-exposure prophylaxis (prevention) trial showed AstraZeneca's sipavibart (formerly AZD3152), an investigational long-acting antibody (LAAB), demonstrated a statistically significant reduction in the incidence of symptomatic COVID‑19 compared to control (tixagevimab/cilgavimab or placebo) in an immunocompromised patient population. The trial met both dual

Interim Report for 1st Quarter 2024

Revenues increased 15.46% and EBIT increased 4.41%Financial report for the period ended 31[st] March 2024 Key Facts for the 1[st] Quarter 2024 (1[st] January – 31[st] March 2024) Revenues increased 15.46% and EBIT increased 4.41% All figures are compared to the same quarter last year if not explicitly stated otherwise. · Revenues increased by 15.46 % to €10,885,611 (€9,428,231) · EBIT increased by 4.41% to €1,568,207 (€1,501,926) · EBIT margin of 14.41% (15.93%) · Net Profit of €824,927 (€1,136,073), decrease of 27.39% · Earnings per share of €0.0110 (€0.0152)

AcadeMedia publishes the Nomination Committee for the AGM 2024

In accordance with the principles adopted by the Annual General Meeting 2022, the Nomination Committee shall comprise one representative for each of the three largest shareholders based on ownership of the company as per the end of the financial year’s third quarter. Should one of the three largest shareholders refrain from appointing a representative to the Nomination Committee, the right shall pass to the shareholder that, excluding these three shareholders, has the largest shareholding in the company and wish to participate in the Nomination Committee. The chairman of the board shall be

There are no items matching the current filter
There are no more items matching the current filter
Back to top